FDA grants orphan drug designation to Boehringer Ingelheim ’s antibody BI 836858

The US Food and Drug Administration (FDA) has granted orphan drug designation to Boehringer Ingelheim ’s anti-CD33 monoclonal antibody, BI 836858, which is being investigated in the treatment of myelodysplastic syndromes (MDS).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news